BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15561831)

  • 1. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.
    Sprandel KA; Schriever CA; Pendland SL; Quinn JP; Gotfried MH; Hackett S; Graham MB; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4597-605. PubMed ID: 15561831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.
    Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
    Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
    Agudelo M; Vesga O
    Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
    Kang SL; Rybak MJ; McGrath BJ; Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2702-9. PubMed ID: 7695250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.
    Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):701-5. PubMed ID: 8851596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
    Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
    Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
    Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative serum bactericidal activity of ceftizoxime/metronidazole, ceftizoxime, clindamycin, and imipenem against obligate anaerobic bacteria.
    Kowalsky SF; Echols RM; McCormick EM
    J Antimicrob Chemother; 1990 May; 25(5):767-75. PubMed ID: 2373663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
    Pea F; Di Qual E; Cusenza A; Brollo L; Baldassarre M; Furlanut M
    Clin Pharmacokinet; 2003; 42(6):589-98. PubMed ID: 12793843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis.
    Nicolle L; Duckworth H; Sitar D; Bryski L; Harding G; Zhanel G
    Int J Antimicrob Agents; 2008 Mar; 31(3):287-9. PubMed ID: 18155885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole.
    Credito KL; Jacobs MR; Appelbaum PC
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):181-3. PubMed ID: 11109019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection.
    Lewis RE; Klepser ME; Ernst EJ; Snabes MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 May; 37(1):51-5. PubMed ID: 10794941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.
    Rodvold KA; Danziger LH; Gotfried MH
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2450-7. PubMed ID: 12878504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.
    Cook AM; Martin C; Adams VR; Morehead RS
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3240-3. PubMed ID: 21576432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.